APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-obesity Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-obesity Medicine Market Analysis and Forecast 2026-2032

1 January 2026192 pages

Choose your research edition.

Industry ResearchAnti-obesity Medicine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-obesity Medicine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Anti-obesity Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-obesity Medicine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-obesity Medicine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Anti-obesity Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti-obesity Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-obesity Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-obesity Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-obesity Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anti-obesity Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-obesity Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-obesity Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-obesity Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-obesity Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-obesity Medicine revenue, projected growth trends, production technology, application and end-user industry.

Anti-obesity Medicine Segment by Company

Eisai

Novo Nordisk

Merck

Roche

Pfizer

GlaxoSmithKline

Vivus

Orexigen Therapeutics

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin Pharmaceuticals

Alizyme

Anti-obesity Medicine Segment by Type

Prescription Drugs

OTC Drugs

Anti-obesity Medicine Segment by Application

Men

Women

Anti-obesity Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti-obesity Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti-obesity Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-obesity Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-obesity Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prescription Drugs Major Player Table 3. OTC Drugs Major Player Table 4. Global Anti-obesity Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Men Major Player Table 6. Women Major Player Table 7. Anti-obesity Medicine Industry Trends Table 8. Anti-obesity Medicine Industry Drivers Table 9. Anti-obesity Medicine Industry Opportunities and Challenges Table 10. Anti-obesity Medicine Industry Restraints Table 11. Global Anti-obesity Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Anti-obesity Medicine Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Anti-obesity Medicine Market Share by Region (2021-2026) Table 14. Global Anti-obesity Medicine Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Anti-obesity Medicine Market Share by Region (2027-2032) Table 16. Global Anti-obesity Medicine Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Anti-obesity Medicine Revenue Market Share by Players (2021-2026) Table 18. Global Anti-obesity Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Anti-obesity Medicine Key Players Headquarters & Area Served Table 20. Global Anti-obesity Medicine Players, Product Type & Application Table 21. Global Anti-obesity Medicine Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Anti-obesity Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Anti-obesity Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Anti-obesity Medicine Revenue Market Share by Type (2021-2026) Table 28. Global Anti-obesity Medicine Revenue Market Share by Type (2027-2032) Table 29. Global Anti-obesity Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Anti-obesity Medicine Revenue Market Share by Application (2021-2026) Table 33. Global Anti-obesity Medicine Revenue Market Share by Application (2027-2032) Table 34. Eisai Company Information Table 35. Eisai Business Overview Table 36. Eisai Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Eisai Anti-obesity Medicine Product Portfolio Table 38. Eisai Recent Development Table 39. Novo Nordisk Company Information Table 40. Novo Nordisk Business Overview Table 41. Novo Nordisk Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novo Nordisk Anti-obesity Medicine Product Portfolio Table 43. Novo Nordisk Recent Development Table 44. Merck Company Information Table 45. Merck Business Overview Table 46. Merck Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Merck Anti-obesity Medicine Product Portfolio Table 48. Merck Recent Development Table 49. Roche Company Information Table 50. Roche Business Overview Table 51. Roche Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Roche Anti-obesity Medicine Product Portfolio Table 53. Roche Recent Development Table 54. Pfizer Company Information Table 55. Pfizer Business Overview Table 56. Pfizer Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Pfizer Anti-obesity Medicine Product Portfolio Table 58. Pfizer Recent Development Table 59. GlaxoSmithKline Company Information Table 60. GlaxoSmithKline Business Overview Table 61. GlaxoSmithKline Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. GlaxoSmithKline Anti-obesity Medicine Product Portfolio Table 63. GlaxoSmithKline Recent Development Table 64. Vivus Company Information Table 65. Vivus Business Overview Table 66. Vivus Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Vivus Anti-obesity Medicine Product Portfolio Table 68. Vivus Recent Development Table 69. Orexigen Therapeutics Company Information Table 70. Orexigen Therapeutics Business Overview Table 71. Orexigen Therapeutics Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Orexigen Therapeutics Anti-obesity Medicine Product Portfolio Table 73. Orexigen Therapeutics Recent Development Table 74. Boehringer Ingelheim Company Information Table 75. Boehringer Ingelheim Business Overview Table 76. Boehringer Ingelheim Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Boehringer Ingelheim Anti-obesity Medicine Product Portfolio Table 78. Boehringer Ingelheim Recent Development Table 79. Arena Pharmaceuticals Company Information Table 80. Arena Pharmaceuticals Business Overview Table 81. Arena Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio Table 83. Arena Pharmaceuticals Recent Development Table 84. Amylin Pharmaceuticals Company Information Table 85. Amylin Pharmaceuticals Business Overview Table 86. Amylin Pharmaceuticals Anti-obesity Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio Table 88. Amylin Pharmaceuticals Recent Development Table 89. Alizyme Company Information Table 90. Alizyme Business Overview Table 91. Alizyme Anti-obesity Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Alizyme Anti-obesity Medicine Product Portfolio Table 93. Alizyme Recent Development Table 94. North America Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 95. North America Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 96. North America Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 97. North America Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 98. North America Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. North America Anti-obesity Medicine Revenue by Country (2021-2026) & (US$ Million) Table 100. North America Anti-obesity Medicine Revenue by Country (US$ Million) & (2027-2032) Table 101. Europe Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 102. Europe Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 103. Europe Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Europe Anti-obesity Medicine Revenue by Country (2021-2026) & (US$ Million) Table 107. Europe Anti-obesity Medicine Revenue by Country (US$ Million) & (2027-2032) Table 108. China Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 109. China Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 110. China Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 111. China Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 113. Asia Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 114. Asia Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 115. Asia Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Anti-obesity Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Asia Anti-obesity Medicine Revenue by Region (US$ Million) & (2021-2026) Table 118. Asia Anti-obesity Medicine Revenue by Region (US$ Million) & (2027-2032) Table 119. SAMEA Anti-obesity Medicine Revenue by Type (2021-2026) & (US$ Million) Table 120. SAMEA Anti-obesity Medicine Revenue by Type (2027-2032) & (US$ Million) Table 121. SAMEA Anti-obesity Medicine Revenue by Application (2021-2026) & (US$ Million) Table 122. SAMEA Anti-obesity Medicine Revenue by Application (2027-2032) & (US$ Million) Table 123. SAMEA Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. SAMEA Anti-obesity Medicine Revenue by Country (2021-2026) & (US$ Million) Table 125. SAMEA Anti-obesity Medicine Revenue by Country (US$ Million) & (2027-2032) Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Anti-obesity Medicine Image Figure 2. Global Anti-obesity Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-obesity Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prescription Drugs Image Figure 5. OTC Drugs Image Figure 6. Global Anti-obesity Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-obesity Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Men Image Figure 9. Women Image Figure 10. Global Anti-obesity Medicine Market Size (US$ Million) & (2021-2032) Figure 11. Global Anti-obesity Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Anti-obesity Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Anti-obesity Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Anti-obesity Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Anti-obesity Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Anti-obesity Medicine Revenue Market Share by Type (2021-2032) Figure 18. Global Anti-obesity Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Anti-obesity Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Anti-obesity Medicine Revenue Market Share by Application (2021-2032) Figure 21. North America Anti-obesity Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Anti-obesity Medicine Revenue Share by Type (2021-2032) Figure 23. North America Anti-obesity Medicine Revenue Share by Application (2021-2032) Figure 24. North America Anti-obesity Medicine Revenue Share by Country (2021-2032) Figure 25. United States Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Anti-obesity Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Anti-obesity Medicine Revenue Share by Type (2021-2032) Figure 30. Europe Anti-obesity Medicine Revenue Share by Application (2021-2032) Figure 31. Europe Anti-obesity Medicine Revenue Share by Country (2021-2032) Figure 32. Germany Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Anti-obesity Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Anti-obesity Medicine Revenue Share by Type (2021-2032) Figure 42. China Anti-obesity Medicine Revenue Share by Application (2021-2032) Figure 43. Asia Anti-obesity Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Anti-obesity Medicine Revenue Share by Type (2021-2032) Figure 45. Asia Anti-obesity Medicine Revenue Share by Application (2021-2032) Figure 46. Asia Anti-obesity Medicine Revenue Share by Region (2021-2032) Figure 47. Japan Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Anti-obesity Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Anti-obesity Medicine Revenue Share by Type (2021-2032) Figure 55. SAMEA Anti-obesity Medicine Revenue Share by Application (2021-2032) Figure 56. SAMEA Anti-obesity Medicine Revenue Share by Country (2021-2032) Figure 57. Brazil Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Anti-obesity Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • OTC Drugs
Applications
  • Men
  • Women
Companies covered
  • Eisai
  • Novo Nordisk
  • Merck
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Vivus
  • Orexigen Therapeutics
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin Pharmaceuticals
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-obesity Medicine Market by Type
  3. 1.2.1 Global Anti-obesity Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prescription Drugs
  5. 1.2.3 OTC Drugs
  6. 1.3 Anti-obesity Medicine Market by Application
  7. 1.3.1 Global Anti-obesity Medicine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Men
  9. 1.3.3 Women
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Anti-obesity Medicine Market Dynamics
  1. 2.1 Anti-obesity Medicine Industry Trends
  2. 2.2 Anti-obesity Medicine Industry Drivers
  3. 2.3 Anti-obesity Medicine Industry Opportunities and Challenges
  4. 2.4 Anti-obesity Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti-obesity Medicine Market Perspective (2021-2032)
  2. 3.2 Global Anti-obesity Medicine Growth Trends by Region
  3. 3.2.1 Global Anti-obesity Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-obesity Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti-obesity Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti-obesity Medicine Revenue by Players
  2. 4.1.1 Global Anti-obesity Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti-obesity Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti-obesity Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-obesity Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti-obesity Medicine Key Players Headquarters & Area Served
  7. 4.4 Global Anti-obesity Medicine Players, Product Type & Application
  8. 4.5 Global Anti-obesity Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti-obesity Medicine Market CR5 and HHI
  11. 4.6.3 2025 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3
5 Anti-obesity Medicine Market Size by Type
  1. 5.1 Global Anti-obesity Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 5.3 Global Anti-obesity Medicine Revenue Market Share by Type (2021-2032)
6 Anti-obesity Medicine Market Size by Application
  1. 6.1 Global Anti-obesity Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti-obesity Medicine Revenue by Application (2021-2032)
  3. 6.3 Global Anti-obesity Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eisai
  2. 7.1.1 Eisai Company Information
  3. 7.1.2 Eisai Business Overview
  4. 7.1.3 Eisai Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Anti-obesity Medicine Product Portfolio
  6. 7.1.5 Eisai Recent Developments
  7. 7.2 Novo Nordisk
  8. 7.2.1 Novo Nordisk Company Information
  9. 7.2.2 Novo Nordisk Business Overview
  10. 7.2.3 Novo Nordisk Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
  12. 7.2.5 Novo Nordisk Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Anti-obesity Medicine Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Anti-obesity Medicine Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Anti-obesity Medicine Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 Vivus
  38. 7.7.1 Vivus Company Information
  39. 7.7.2 Vivus Business Overview
  40. 7.7.3 Vivus Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Vivus Anti-obesity Medicine Product Portfolio
  42. 7.7.5 Vivus Recent Developments
  43. 7.8 Orexigen Therapeutics
  44. 7.8.1 Orexigen Therapeutics Company Information
  45. 7.8.2 Orexigen Therapeutics Business Overview
  46. 7.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
  48. 7.8.5 Orexigen Therapeutics Recent Developments
  49. 7.9 Boehringer Ingelheim
  50. 7.9.1 Boehringer Ingelheim Company Information
  51. 7.9.2 Boehringer Ingelheim Business Overview
  52. 7.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
  54. 7.9.5 Boehringer Ingelheim Recent Developments
  55. 7.10 Arena Pharmaceuticals
  56. 7.10.1 Arena Pharmaceuticals Company Information
  57. 7.10.2 Arena Pharmaceuticals Business Overview
  58. 7.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
  60. 7.10.5 Arena Pharmaceuticals Recent Developments
  61. 7.11 Amylin Pharmaceuticals
  62. 7.11.1 Amylin Pharmaceuticals Company Information
  63. 7.11.2 Amylin Pharmaceuticals Business Overview
  64. 7.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
  66. 7.11.5 Amylin Pharmaceuticals Recent Developments
  67. 7.12 Alizyme
  68. 7.12.1 Alizyme Company Information
  69. 7.12.2 Alizyme Business Overview
  70. 7.12.3 Alizyme Anti-obesity Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Alizyme Anti-obesity Medicine Product Portfolio
  72. 7.12.5 Alizyme Recent Developments
8 North America
  1. 8.1 North America Anti-obesity Medicine Revenue (2021-2032)
  2. 8.2 North America Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti-obesity Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti-obesity Medicine Revenue by Type (2027-2032)
  5. 8.3 North America Anti-obesity Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti-obesity Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti-obesity Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti-obesity Medicine Revenue by Application (2027-2032)
  9. 8.5 North America Anti-obesity Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti-obesity Medicine Revenue by Country
  11. 8.6.1 North America Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti-obesity Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti-obesity Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Anti-obesity Medicine Revenue (2021-2032)
  2. 9.2 Europe Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti-obesity Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti-obesity Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe Anti-obesity Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti-obesity Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti-obesity Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti-obesity Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe Anti-obesity Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti-obesity Medicine Revenue by Country
  11. 9.6.1 Europe Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti-obesity Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti-obesity Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Anti-obesity Medicine Revenue (2021-2032)
  2. 10.2 China Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China Anti-obesity Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China Anti-obesity Medicine Revenue by Type (2027-2032)
  5. 10.3 China Anti-obesity Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China Anti-obesity Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China Anti-obesity Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China Anti-obesity Medicine Revenue by Application (2027-2032)
  9. 10.5 China Anti-obesity Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-obesity Medicine Revenue (2021-2032)
  2. 11.2 Asia Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti-obesity Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti-obesity Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia Anti-obesity Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti-obesity Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti-obesity Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti-obesity Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia Anti-obesity Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti-obesity Medicine Revenue by Country
  11. 11.6.1 Asia Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti-obesity Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti-obesity Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-obesity Medicine Revenue (2021-2032)
  2. 12.2 SAMEA Anti-obesity Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti-obesity Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti-obesity Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti-obesity Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti-obesity Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti-obesity Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti-obesity Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti-obesity Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti-obesity Medicine Revenue by Country
  11. 12.6.1 SAMEA Anti-obesity Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti-obesity Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti-obesity Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst